1. Home
  2. VERU vs CRT Comparison

VERU vs CRT Comparison

Compare VERU & CRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERU
  • CRT
  • Stock Information
  • Founded
  • VERU 1971
  • CRT 1991
  • Country
  • VERU United States
  • CRT United States
  • Employees
  • VERU N/A
  • CRT N/A
  • Industry
  • VERU Biotechnology: Pharmaceutical Preparations
  • CRT Oil & Gas Production
  • Sector
  • VERU Health Care
  • CRT Energy
  • Exchange
  • VERU Nasdaq
  • CRT Nasdaq
  • Market Cap
  • VERU 40.6M
  • CRT 42.5M
  • IPO Year
  • VERU 1990
  • CRT 1992
  • Fundamental
  • Price
  • VERU $2.17
  • CRT $8.82
  • Analyst Decision
  • VERU Strong Buy
  • CRT
  • Analyst Count
  • VERU 2
  • CRT 0
  • Target Price
  • VERU $25.00
  • CRT N/A
  • AVG Volume (30 Days)
  • VERU 191.3K
  • CRT 43.2K
  • Earning Date
  • VERU 12-15-2025
  • CRT 01-01-0001
  • Dividend Yield
  • VERU N/A
  • CRT 8.40%
  • EPS Growth
  • VERU N/A
  • CRT N/A
  • EPS
  • VERU N/A
  • CRT 0.74
  • Revenue
  • VERU $16,886,419.00
  • CRT $5,621,913.00
  • Revenue This Year
  • VERU N/A
  • CRT N/A
  • Revenue Next Year
  • VERU N/A
  • CRT N/A
  • P/E Ratio
  • VERU N/A
  • CRT $11.93
  • Revenue Growth
  • VERU 337.24
  • CRT N/A
  • 52 Week Low
  • VERU $2.11
  • CRT $7.07
  • 52 Week High
  • VERU $14.20
  • CRT $13.31
  • Technical
  • Relative Strength Index (RSI)
  • VERU 25.21
  • CRT 69.22
  • Support Level
  • VERU $2.11
  • CRT $7.55
  • Resistance Level
  • VERU $2.57
  • CRT $9.05
  • Average True Range (ATR)
  • VERU 0.20
  • CRT 0.28
  • MACD
  • VERU -0.03
  • CRT 0.09
  • Stochastic Oscillator
  • VERU 9.33
  • CRT 77.05

About VERU Veru Inc.

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

About CRT Cross Timbers Royalty Trust

Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.

Share on Social Networks: